公开(公告)号：US20140010826A1

公开(公告)日：2014-01-09

申请号：US13936084

申请日：2013-07-05

Applicant: Biogen Idec MA Inc.

Inventor： Sha MI ,  Kenneth J. Rhodes ,  R. Blake Pepinsky

IPC: A61K39/395 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/17

CPC classification number: C07K16/2878 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K38/177 ,  A61K39/39541 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/70578 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的死亡受体-6（DR6）蛋白，现在已被证明对调节神经系统细胞凋亡是重要的。 此外，已经发现p75是DR6的配体。 因此，本发明涉及使用DR6和/或p75拮抗剂抑制DR6和p75相互作用的方法。 此外，本文所述的方法包括使用DR6拮抗剂（任选与p75拮抗剂组合）促进神经系统细胞存活的方法，以及任选地与p75拮抗剂组合施用DR6拮抗剂治疗神经变性病症的方法 。

公开(公告)号：US20130302281A1

公开(公告)日：2013-11-14

申请号：US13944569

申请日：2013-07-17

Applicant: BIOGEN IDEC MA INC.

Inventor： Mary D. DiBiase ,  Wen-Li Chung ,  Mark Staples ,  Eric Scharin

IPC: A61K38/21

CPC classification number: A61K38/215 ,  A61K9/0019 ,  A61K38/21 ,  A61K47/10 ,  A61K47/183 ,  C07K14/565

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

公开(公告)号：US20130295169A1

公开(公告)日：2013-11-07

申请号：US13827228

申请日：2013-03-14

Applicant: Biogen Idec MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K9/48 ,  A61K31/616 ,  A61K9/20

CPC classification number: A61K31/225 ,  A61K9/16 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2833 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

公开(公告)号：US20130287796A1

公开(公告)日：2013-10-31

申请号：US13829146

申请日：2013-03-14

Applicant: Biogen Idec MA Inc.

Inventor： Sha MI ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber ,  Steven D. Miklasz ,  Christilyn Graff

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

公开(公告)号：US20130237477A1

公开(公告)日：2013-09-12

申请号：US13679529

申请日：2012-11-16

Applicant: BIOGEN IDEC MA INC. ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

Inventor： Anthony Rossomando ,  Jean-Sebastien Silvestre ,  Radia Tamarat

IPC: A61K38/18 ,  A61K45/06

CPC classification number: A61K38/185 ,  A61K45/06 ,  C07K14/475

Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.

Abstract translation: 公开了通过向显示组织中的血流受损或不足的哺乳动物施用新伯斯加蛋白多肽来增加组织中的血管形成的方法。 该方法可以用于治疗或预防以血液流通受损或不充分为特征的疾病，或增加移植到受试者中的器官中的血管形成。

公开(公告)号：US20130065219A1

公开(公告)日：2013-03-14

申请号：US13659655

申请日：2012-10-24

Applicant: Biogen Idec MA Inc.

Inventor： Valerie Liu TSANG ,  Angela Xiaoying WANG ,  Helena YUSUF-MAKAGIANSAR

IPC: C12Q3/00

CPC classification number: C12P21/02 ,  C07K16/00 ,  Y10T436/115831 ,  Y10T436/116664 ,  Y10T436/117497 ,  Y10T436/12

Abstract: The present invention pertains to methods of increasing the efficiency of producing a bioproduct. In some embodiments, the method increases the quantity of a bioproduct produced, or decreases bioproduct production time, in a bioreactor cell culture producing the bioproduct, the method comprising, (a) intermittently or continuously analyzing the concentration of one or more nutrients in the bioreactor cell culture; and (b) adding to the bioreactor cell culture additional nutrient media when the concentration of the one or more nutrients is lower than a target value.

Abstract translation: 本发明涉及提高生物制品生产效率的方法。 在一些实施方案中，该方法在产生生物产物的生物反应器细胞培养物中增加产生的生物产物的量或减少生物产物生产时间，该方法包括：（a）间歇地或连续地分析生物反应器中一种或多种营养物质的浓度 细胞培养; 和（b）当一种或多种营养素的浓度低于目标值时，向生物反应器细胞培养添加另外的营养培养基。

公开(公告)号：US20130045219A1

公开(公告)日：2013-02-21

申请号：US13656922

申请日：2012-10-22

Applicant: UCB Pharma S.A. ,  Biogen Idec MA Inc.

Inventor： LINDA C. BURKLY ,  JANINE L. FERRANT-ORGETTAS ,  ELLEN A. GARBER ,  YEN-MING HSU ,  LIHE SU ,  FREDERICK R. TAYLOR ,  RALPH ADAMS ,  DEREK THOMAS BROWN ,  ANDREW GEORGE POPPLEWELL ,  MARTYN KIM ROBINSON ,  ANTHONY SHOCK ,  KERRY LOUISE TYSON

IPC: C07K16/28 ,  C12N15/63 ,  C12N1/21 ,  C12N1/15 ,  C12N1/19 ,  C12N5/10 ,  C12P21/00 ,  A61K39/395 ,  A61P29/00 ,  A61P37/06 ,  A61P19/02 ,  A61P19/04 ,  A61P1/00 ,  A61P17/06 ,  A61P25/00 ,  C12N15/12

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。

公开(公告)号：US20040234554A1

公开(公告)日：2004-11-25

申请号：US10872550

申请日：2004-06-21

Applicant: Biogen Idec MA Inc.

Inventor： Kenneth Murray

IPC: A61K039/29

CPC classification number: A61K39/385 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/5258 ,  A61K2039/6075 ,  A61K2039/627 ,  A61K2039/64 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/70 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  G01N33/56983 ,  G01N2333/02 ,  G01N2469/20 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/396 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/472 ,  Y02A50/484 ,  Y02A50/52 ,  Y02A50/53 ,  Y02A50/54 ,  Y02A50/58 ,  Y02A50/59 ,  Y02A50/60 ,  Y10S530/806 ,  Y10S530/81

Abstract: This invention relates to hepatitis B virus (nullHBVnull) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.

Abstract translation: 本发明涉及以多种免疫原特异性为特征的乙型肝炎病毒（“HBV”）核心抗原颗粒。 更具体地，本发明涉及包含免疫原，表位或其它相关结构的HBV核心抗原颗粒，其通过配体选择性地结合HBV核心蛋白的配体进行交联。 这样的颗粒可以用作各种免疫原性表位的递送系统，包括HBV衣壳结合肽，其有利地还通过阻断HBV核心蛋白和HBV表面蛋白之间的相互作用来抑制和干扰HBV病毒组装。 不同免疫原和/或衣壳结合肽配体的混合物可以交联到相同的HBV核心颗粒。 这样得到的多组分或多价HBV核心颗粒可以有利地用于治疗和预防性疫苗和组合物，以及使用它们的诊断组合物和方法中。

公开(公告)号：US09567391B2

公开(公告)日：2017-02-14

申请号：US14386228

申请日：2013-03-15

Applicant: Biogen Idec MA Inc.

Inventor： Kenneth Simon ,  Thomas Cameron ,  Mia Rushe ,  Justin Caravella ,  George Campbell Kaynor

IPC: A61K39/395 ,  C07K16/08 ,  A61K39/00

CPC classification number: C07K16/084 ,  A61K2039/505 ,  C07K2317/00 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/76 ,  C07K2317/92

Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.

Abstract translation: 一方面，本公开提供了针对JCV的中和抗体和用于治疗PML的方法。 在一些实施方案中，本发明的方面涉及针对JCV衣壳蛋白VPI（JCV-VP1）的分离的JC-病毒中和单克隆抗体。 在一些实施方案中，抗体抑制JC-病毒的感染性。 在一些实施方案中，抗体结合JCV-VPI的唾液酸结合口袋。 在一些实施方案中，抗体结合包含一个或多个以下突变的JCV-VP1：S269F，S269Y，S267F，N265D，Q271H，D66H，K60E，K60N和L55F。

公开(公告)号：US09421273B2

公开(公告)日：2016-08-23

申请号：US14363546

申请日：2012-12-14

Applicant: Biogen Idec MA Inc.

Inventor： Jianhua Chao

IPC: C07F7/04 ,  A61K47/48 ,  C07F7/08 ,  C07F7/18

CPC classification number: A61K47/48023 ,  A61K47/54 ,  C07F7/0836 ,  C07F7/1804 ,  C07F7/1896

Abstract: The present invention is directed to silicon-containing fumaric acid esters of the Formulae I-IV. The silicon-containing fumaric acid esters of Formulae I-IV are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases. (I), (II), (III) & (IV).

Abstract translation: 本发明涉及式I-Ⅳ的含硅富马酸酯。 式I-IV的含硅富马酸酯可用于移植医学和用于治疗自身免疫疾病和自身免疫相关疾病。 （I），（II），（III）和（IV）。